A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Radiographic Axial Spondyloarthritis (Ankylosing Spondylitis)

Status: Recruiting
Location: See all (37) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

Researchers are looking for new ways to treat radiographic axial spondyloarthritis (r-axSpA). R-axSpA is a type of arthritis that causes pain, stiffness, and inflammation (swelling) in the spine and joints in the pelvis (hip bone). Radiographic means the damage it causes can be seen on X-rays. This study will help find out if a study medicine called tulisokibart can treat symptoms of r-axSpA. Researchers will look at different doses of tulisokibart. Researchers want to know if at least one of the study doses of tulisokibart works better than a placebo to improve r-axSpA symptoms. A placebo looks like the study medicine but has no study medicine in it. Using a placebo helps researchers better understand the effects of the study medicine.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:

⁃ The main inclusion criteria include but are not limited to the following:

• Has a clinical diagnosis of axial spondyloarthritis (axSpA) and meets the Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axSpA including ≥3 months of back pain with age at symptom onset \<45 years

• Meets the radiographic criterion of the modified New York criteria for ankylosing spondylitis (AS) as determined by central reading at Screening

• Has active disease at Screening and Randomization

• Has a history of inadequate response (IR)/intolerance to nonsteroidal anti-inflammatory drugs (NSAIDs) and is biologic disease-modifying antirheumatic drug (bDMARD)-naive, or has a history of IR/intolerance to up to a maximum of 2 bDMARD classes

Locations
United States
Arizona
AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Chandler ( Site 0036)
RECRUITING
Chandler
AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Flagstaff ( Site 0021)
RECRUITING
Flagstaff
Arizona Arthritis & Rheumatology Associates, P.C. - Gilbert ( Site 0022)
RECRUITING
Gilbert
AARA Arizona Arthritis & Rheumatology Associates, P.C. - Glendale ( Site 0056)
RECRUITING
Glendale
Arizona Arthritis & Rheumatology Associates, P.C. - Tucson ( Site 0025)
RECRUITING
Tucson
California
TriWest Research Associates - Chula Vista ( Site 0013)
RECRUITING
Chula Vista
Newport Huntington Medical Group ( Site 0005)
RECRUITING
Huntington Beach
Cohen Medical Centers ( Site 0034)
RECRUITING
Thousand Oaks
Inland Rheumatology Clinical Trials, Inc. ( Site 0002)
RECRUITING
Upland
Florida
Arthritis and Rheumatic Disease Specialties ( Site 0016)
RECRUITING
Aventura
GNP Research - Hollywood ( Site 0020)
RECRUITING
Cooper City
Innovation Medical Research Center ( Site 0012)
RECRUITING
Palmetto Bay
Illinois
Willow Rheumatology and Wellness, PLLC ( Site 0035)
RECRUITING
Willowbrook
Missouri
Kansas City Physician Partners ( Site 0027)
RECRUITING
Kansas City
Nebraska
Physician Research Collaboration, LLC ( Site 0057)
RECRUITING
Lincoln
New Mexico
Inspire Santa Fe Medical Group ( Site 0011)
RECRUITING
Santa Fe
Pennsylvania
Altoona Center for Clinical Research ( Site 0004)
RECRUITING
Duncansville
Texas
Arthritis Care of Texas ( Site 0048)
RECRUITING
Corpus Christi
Epic Medical Research ( Site 0061)
RECRUITING
Red Oak
Other Locations
Canada
G.R.M.O. (Groupe de recherche en maladies osseuses) Inc. ( Site 0200)
RECRUITING
Québec
Centre de Recherche Musculo-Squelettique ( Site 0202)
RECRUITING
Trois-rivières
Germany
Rheumatologische Schwerpunktpraxis ( Site 0605)
RECRUITING
Berlin
Netherlands
Zuyderland Medical Centre ( Site 1100)
RECRUITING
Heerlen
Poland
MICS Centrum Medyczne Torun ( Site 1202)
RECRUITING
Torun
Narodowy Instytut Geriatrii Reumatologii i Rehabilitacji im.Prof. El. Reicher-ul.Spartanska 1 ( Site 1205)
RECRUITING
Warsaw
Republic of Korea
Hanyang University Seoul Hospital ( Site 2800)
RECRUITING
Seoul
Kyung Hee University Hosptial at Gangdong ( Site 2802)
RECRUITING
Seoul
Taiwan
Taipei Veterans General Hospital ( Site 2906)
RECRUITING
Taipei
Ukraine
Communal Nonprofit Enterprise Cherkasy Regional Hospital of Cherkasy Oblast Council ( Site 1704)
RECRUITING
Cherkasy
Municipal Non-Profit Enterprise Khmelnytskyi Regional Hospital of Khmelnytskyi Regional Council ( Site 1713)
RECRUITING
Khmelnytskiy
Kyiv Railway Clinical Hospital No.2 of Branch Health Center of the Public Joint Stock Company Ukrain ( Site 1701)
RECRUITING
Kyiv
Medical Center of Limited Liability Company Medical Center Consilium Medical ( Site 1715)
RECRUITING
Kyiv
Medical Center Universal Clinic Oberig of Limited Liability Company Kapytal ( Site 1706)
RECRUITING
Kyiv
Lviv Clin Hospital of Planned Treatment Rehabilitation Palliative Care ( Site 1710)
RECRUITING
Lviv
ME Ternopil Regional Clinical Hospital of Ternopil Regional Council ( Site 1707)
RECRUITING
Ternopil
Municipal Public Non-Profit Enterprise City Clinical Hospital №1 of the Ivano-Frankivsk City Counc ( Site 1705)
RECRUITING
Ukraine
Municipal Nonprofit Enterprise Vinnytsia Regional Clinical Hospital n.a. M. I. Pyrohov of Vinnytsia ( Site 1700)
RECRUITING
Vinnytsa
Contact Information
Primary
Toll Free Number
Trialsites@msd.com
1-888-577-8839
Time Frame
Start Date: 2025-09-26
Estimated Completion Date: 2030-02-05
Participants
Target number of participants: 315
Treatments
Experimental: High-dose tulisokibart
Participants receive a high dose of tulisokibart.
Experimental: Medium-dose tulisokibart
Participants receive a medium dose of tulisokibart.
Experimental: Low-dose tulisokibart
Participants receive a low dose of tulisokibart and are rerandomized at week 16 to a medium or high dose of tulisokibart.
Placebo_comparator: Placebo
Participants receive a matched placebo dose and are rerandomized at week 16 to a medium or high dose of tulisokibart.
Sponsors
Leads: Merck Sharp & Dohme LLC

This content was sourced from clinicaltrials.gov